Advanced Proteome Therapeutics Corporation planned, Dr. Benjamin Krantz has taken over the role of CEO at its US subsidiary, Advanced Proteome Therapeutics Inc. ("APTI"). Prior to this appointment, Benjamin Krantz MD, MBA was the Chief Fellow in hematology/oncology at New York University Langone Medical Center and served on the Board of Directors of APTI. His research has focused on biomarker and therapeutic development in pancreas ductal adenocarcinoma and has resulted in peer-reviewed articles on novel therapeutics for pancreas cancer and emerging biomarkers for therapeutic selection.